TrialESMO open2021

Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study.

H Jeong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.